News
Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...
Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
Q2 2025 Earnings Call Transcript August 6, 2025 Exact Sciences Corporation beats earnings expectations. Reported EPS is $0.22 ...
Investor's Business Daily on MSN2d
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...
Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback